Grifols registered an increase of nearly 5% on the stock exchange this Tuesday after receiving approval from the U.S. Food and Drug Administration (FDA) for its fibrin sealant, designed to control surgical bleeding in pediatric patients. This authorization expands the use of the product, which until now was only available for adults in the United States.
Grifols' fibrin sealant, which is marketed as Vistaseal in the United States and Canada, and Veraseal in Europe and other markets, is distributed by Johnson & Johnson MedTech through a strategic collaboration established in 2019. This expansion in its use allows hospitals and medical professionals in multiple regions to have access to this option to improve bleeding control in pediatric surgeries.
In stock market terms, Grifols' class 'A' shares on the Ibex 35 rose 4.05%, reaching 10.405 euros, while class 'B' shares on the Continuous Market increased in value by 4.9%, up to 8.245 euros. This increase occurred a day after a 2.39% decline in the Ibex 35, influenced by the possibility of a delay in the takeover bid (OPA) from the Canadian fund Brookfield on the company.
FDA approval strengthens Grifols' position in the biosurgery market and demonstrates how scientific backing and strategic collaboration can facilitate access to new therapies in various regions.